Patents Examined by Terra Cotta Gibbs
  • Patent number: 8519111
    Abstract: Methods and compositions are provided that allow for high-level expression of a factor VIII polypeptide. More specifically, methods and compositions are provided comprising nucleic acid and amino acid sequences comprising a modified factor VIII that result in high-level expression of the polypeptide. The methods and compositions of the invention find use in the treatment of factor VIII deficiency including, for example, hemophilia A.
    Type: Grant
    Filed: May 27, 2012
    Date of Patent: August 27, 2013
    Assignee: Expression Therapeutics LLC
    Inventor: John S Lollar
  • Patent number: 8518904
    Abstract: Compounds, compositions and methods are provided for modulating the expression of STAT 6. The compositions comprise oligonucleotides, targeted to nucleic acid encoding STAT 6. Methods of using these compounds for modulation of STAT 6 expression and for diagnosis and treatment of disease associated with expression of STAT 6 are provided.
    Type: Grant
    Filed: January 13, 2012
    Date of Patent: August 27, 2013
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: William R. Shanahan, Jr., Susan M. Freier, Kenneth W. Dobie
  • Patent number: 8518907
    Abstract: The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of CTNNB1 gene expression and/or activity, and/or modulate a beta-catenin gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules that are capable of mediating or that mediate RNA interference (RNAi) against CTNNB1 gene expression.
    Type: Grant
    Filed: August 2, 2011
    Date of Patent: August 27, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Duncan Brown, James J. Cunningham, Marian Gindy, Victoria Pickering, Matthew G. Stanton, Steven M. Stirdivant, Walter R. Strapps
  • Patent number: 8507455
    Abstract: The present invention provides iRNA agent including at least one monomer having the structure shown in formula (I?) wherein: A and B are each independently for each occurrence O, N(RN) or S; X is H, a protecting group, a phosphate group, a phosphodiester group, an activated phosphate group, an activated phosphite group, a phosphoramidite, a solid support, —P(Z?)(Z?)O-nucleoside, —P(Z?)(Z?)O-oligonucleotide, a lipid, a PEG, a steroid, a polymer, —P(Z?)(Z?)O-L6-Q?-L7-OP(Z??)(Z???)O-oligonucleotide, a nucleotide, or an oligonucleotide; Y is H, a protecting group, a phosphate group, a phosphodiester group, an activated phosphate group, an activated phosphite group, a phosphoramidite, a solid support, —P(Z?)(Z?)O-nucleoside, —P(Z?)(Z?)O-oligonucleotide, a lipid, a PEG, a steroid, a lipophile, a polymer, —P(Z?)(Z?)O-L6-Q?-L7-OP(Z??)(Z???)O-oligonucleotide, a nucleotide, or an oligonucleotide; R is folate, a folate analog a folate mimic or a folate receptor binding ligand; L6 and L7 are each independently for ea
    Type: Grant
    Filed: December 4, 2008
    Date of Patent: August 13, 2013
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, Muthusamy Jayaraman, Jayaprakash K. Narayanannair
  • Patent number: 8501704
    Abstract: Provided are methods and antisense oligonucleotide analogs for suppressing an immune response in a mammalian subject, for the treatment or prevention of an autoimmune condition or transplantation rejection. The oligonucleotide analogs provided herein comprise a targeting sequence complementary to a preprocessed CTLA-4 mRNA region that spans the splice junction between intron 1 and exon 2 of the preprocessed CTLA-4 mRNA. Also provided are methods of use, in which the oligonucleotides are effective, when administered to a subject, to form within host cells, a heteroduplex structure (i) composed of the preprocessed CTLA-4 mRNA and the oligonucleotide compound, (ii) characterized by a Tm of dissociation of at least 45° C., and (iii) resulting in an increased ratio of processed mRNA encoding ligand-independent CTLA-4 to processed mRNA encoding full-length CTLA-4.
    Type: Grant
    Filed: November 7, 2008
    Date of Patent: August 6, 2013
    Assignee: Sarepta Therapeutics, Inc.
    Inventors: Dan V. Mourich, Patrick L. Iversen, Dwight D. Weller
  • Patent number: 8486910
    Abstract: Polynucleotides and a method suitable for downregulation of small nuclear RNA which can be used to treat diseases associated with activity of small nuclear RNA are provided. Specifically, the present invention can be used to downregulate snoRNA molecules or box H/ACA-containing RNA molecules which are involved in diseases such as cancer.
    Type: Grant
    Filed: March 12, 2012
    Date of Patent: July 16, 2013
    Assignee: Bar-Ilan University
    Inventor: Shulamit Michaeli
  • Patent number: 8481508
    Abstract: Provided are methods and compositions for the treatment or prevention of macular degeneration or other diseases or disorders associated with activation of TLR3. Administration of double stranded RNAs having a length of 22 nucleotides or less treats or prevents macular degeneration or other diseases or disorders associated with activation of TLR3 due to the ability of the RNAs to bind to but not activate TLR3. Furthermore, all double stranded RNAs (both targeted and non-targeted) of 22 nucleotides or less in length can bind to but not activate TLR3 and thereby treat or prevent such conditions. Also provided of a method for increasing the specificity of a desire siRNA target knockdown, the method comprising administering an amount of a target siRNA sufficient to knockdown a target gene and an amount of a double stranded RNA of 22 nucleotides or less which prevents the target siRNA from activating TLR3.
    Type: Grant
    Filed: February 20, 2009
    Date of Patent: July 9, 2013
    Assignee: University of Kentucky Research Foundation
    Inventor: Jayakrishna Ambati
  • Patent number: 8481506
    Abstract: Provided herein are isolated viral and human nucleic acids associated with viral infection and various nucleic acid molecules relating thereto or derived therefrom. The nucleic acids may be useful for the prevention, treatment and diagnosis of viral infections.
    Type: Grant
    Filed: December 5, 2007
    Date of Patent: July 9, 2013
    Assignee: Rosetta Genomics, Ltd.
    Inventors: Issac Bentwich, Amir Avniel, Ranit Aharonov, Yael Karov, Yonat Shemer-Avni, Asal Levy
  • Patent number: 8481505
    Abstract: The invention provides methods and compositions for the treatment of cancers associated with overexpression of a BCL2 gene and/or gene product in a subject, and methods and compositions for the improvement of anti-cancer therapy, such as chemotherapy and radiation therapy. The invention also encompasses methods for determining the efficacy of a cancer therapy in a subject and methods for inducing apoptosis of a cell.
    Type: Grant
    Filed: September 11, 2006
    Date of Patent: July 9, 2013
    Assignee: The Ohio State University Research Foundation
    Inventors: Carlo M. Croce, George A. Calin
  • Patent number: 8476417
    Abstract: Provided herein are isolated genomic polynucleotide fragments from the from the p15 region of chromosome 11 encoding human and tumor suppressing subtransferable candidate 4 (TSSC4) and methods of use.
    Type: Grant
    Filed: September 24, 2011
    Date of Patent: July 2, 2013
    Inventor: James Ryan
  • Patent number: 8476243
    Abstract: A method for keratin hyperproliferation disorders such as corns, calluses, or keratosis pilaris (KP) by administering to a subject experiencing the disorder a therapeutically effective amount of an RNA sequence which inhibits expression of a gene encoding for a keratin selected from the group consisting of K6a, K6b, K16, K17, and combinations thereof.
    Type: Grant
    Filed: December 29, 2006
    Date of Patent: July 2, 2013
    Assignee: Transderm, Inc.
    Inventors: Roger Louis Kaspar, Robyn Patricia Hickerson
  • Patent number: 8470792
    Abstract: Disclosed herein are siRNA compositions and methods useful for inhibiting expression of vascular endothelial growth factor (VEGF) isoforms. Such compositions and methods further involve siRNA capable of selectively targeting angiogenic VEGF isoforms while selectively sparing anti-angiogenic isoforms. Diseases which involve angiogenesis stimulated by overexpression of VEGF, such as diabetic retinopathy, age related macular degeneration and many types of cancer, can be treated by administering small interfering RNAs as disclosed.
    Type: Grant
    Filed: December 4, 2009
    Date of Patent: June 25, 2013
    Assignee: Opko Pharmaceuticals, LLC.
    Inventors: Phillip Frost, Nadine Dejneka, Ottrina S. Bond, Naveed Shams
  • Patent number: 8470799
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the HAMP gene (HAMP gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the HAMP gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by HAMP gene expression and the expression of the HAMP gene using the pharmaceutical composition.
    Type: Grant
    Filed: August 21, 2012
    Date of Patent: June 25, 2013
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Tomoko Nakayama, Anke Geick, Pamela Tan, Herbert Y. Lin
  • Patent number: 8466117
    Abstract: The invention generally features compositions and methods that are useful for modulating angiogenesis.
    Type: Grant
    Filed: July 30, 2007
    Date of Patent: June 18, 2013
    Assignees: The Johns Hopkins University, The Trustees of the University of Pennsylvania
    Inventors: Joshua T. Mendell, Erik A. Wentzel, Andrei Thomas-Tikhonenko, Michael Dews, Asal Homayouni
  • Patent number: 8455454
    Abstract: Embodiments of the invention provide methods of preventing or treating detrimental epithelial cell proliferation, loss of epithelial cell differentiation, age-related macular degeneration and/or proliferative vitreal retinopathy in an individual comprising administering to an individual in need thereof an effective amount of miR 204, an effective amount of miR 211, or an effective amount of a mixture of miR 204 and miR 211. A further embodiment of the invention provides a method of facilitating the transport of a substance across an epithelium in an individual comprising administrating to an individual an effective amount of anti-miR 204, an effective amount of anti-miR 211, or an effective amount of a mixture of anti-miR 204 and anti-miR 211. Additional embodiments of the invention include pharmaceutical compositions of miR 204 and/or miR 211 and pharmaceutical compositions of anti-miR 204 and/or anti-miR 211.
    Type: Grant
    Filed: August 26, 2009
    Date of Patent: June 4, 2013
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Fei Wang, Sheldon Miller, Congxiao Zhang, Arvydas Maminishkis
  • Patent number: 8440637
    Abstract: The present invention relate to the use of a combination of an inhibitor of miR-122 and an inhibitor of VLDL assembly, for the treatment of HCV, hyperlipidemia and hypercholesterolemia.
    Type: Grant
    Filed: October 3, 2008
    Date of Patent: May 14, 2013
    Assignee: Santaris Pharma A/S
    Inventor: Joacim Elmén
  • Patent number: 8426379
    Abstract: The present invention provides methods and compositions for diagnosis and treatment of carcinomas with aberrant expression patterns of POT 1. The invention also provides methods of identifying compounds that may modulate the cellular expression of POT 1. The invention further provides methods for treating subjects suffering from or at risk of developing a colorectal carcinoma.
    Type: Grant
    Filed: February 15, 2011
    Date of Patent: April 23, 2013
    Assignee: The United States of America, as represented by the Secretary, Department of Health & Human Services
    Inventors: Qin Yang, Curtis C. Harris
  • Patent number: 8420613
    Abstract: The present invention provides methods for reducing the level of amyloid beta protein in a cell or tissue, the methods generally involving contacting the cell or tissue with an agent that reduces cystatin C levels and/or activity. The present invention provides methods for treating Alzheimer's disease (AD), and methods for treating cerebral angiopathy, in an individual, the methods generally involving administering to an individual having AD a therapeutically effective amount of an agent that reduces cystatin C levels and/or activity. The present invention further provides methods for identifying an agent that reduces cystatin C levels and/or activity.
    Type: Grant
    Filed: November 15, 2007
    Date of Patent: April 16, 2013
    Assignee: The J. David Gladstone Institutes
    Inventors: Li Gan, Lennart Mucke
  • Patent number: 8420594
    Abstract: The invention relates to inhibitors of Multi drug Resistant Protein 4 (MRP4) for the treatment and/or the prevention of cardiac disorders, such as acute or chronic heart failure and cardiogenic shock. The invention also relates to agents stimulating MRP4 activity for the treatment and/or the prevention of cardiac hypertrophy.
    Type: Grant
    Filed: July 17, 2009
    Date of Patent: April 16, 2013
    Assignee: INSERM (Institute de la Sante et de la Recherche Medicale)
    Inventors: Jean-Sebastien Hulot, Anne-Marie Lompre, Yassine Sassi
  • Patent number: 8415313
    Abstract: A method and composition for inducing human dendritic cells to a condition of reduced capacity for antigen-specific activation of T cells, and, in mature dendritic cells, increased production of extracellular IL-10 is disclosed. A population of dendritic cells is exposed to a substantially uncharged antisense compound, including partially positively charged, containing 12-40 subunits and a base sequence effective to hybridize to a target region within the sequence identified by SEQ ID NO:9, to form a duplex structure between the compound and transcript having a Tm of at least 45° C. Formation of the duplex blocks expression of full-length CD86 in the cells, which in turn leads to reduced capacity for antigen-specific activation of T cells, and, in mature dendritic cells, increased production of extracellular IL-10.
    Type: Grant
    Filed: May 11, 2006
    Date of Patent: April 9, 2013
    Assignee: AVI BioPharma, Inc.
    Inventors: Dan V. Mourich, Patrick L. Iversen, Dwight D. Weller